Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Siddharth Singh, Darrell S. Pardi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

Original languageEnglish (US)
Pages (from-to)457-478
Number of pages22
JournalGastroenterology Clinics of North America
Volume43
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Comparative Effectiveness Research
Hospitalization
Quality of Life
Pediatrics
Therapeutics
Certolizumab Pegol
Infliximab
Adalimumab

Keywords

  • Adalimumab
  • Anti-tumor necrosis factor
  • Certolizumab pegol
  • Crohn disease
  • Infliximab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease. / Singh, Siddharth; Pardi, Darrell S.

In: Gastroenterology Clinics of North America, Vol. 43, No. 3, 2014, p. 457-478.

Research output: Contribution to journalArticle

Singh, Siddharth ; Pardi, Darrell S. / Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease. In: Gastroenterology Clinics of North America. 2014 ; Vol. 43, No. 3. pp. 457-478.
@article{d865dea380964caea3e68c3350b9ac3a,
title = "Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease",
abstract = "Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.",
keywords = "Adalimumab, Anti-tumor necrosis factor, Certolizumab pegol, Crohn disease, Infliximab",
author = "Siddharth Singh and Pardi, {Darrell S.}",
year = "2014",
doi = "10.1016/j.gtc.2014.05.008",
language = "English (US)",
volume = "43",
pages = "457--478",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

AU - Singh, Siddharth

AU - Pardi, Darrell S.

PY - 2014

Y1 - 2014

N2 - Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

AB - Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

KW - Adalimumab

KW - Anti-tumor necrosis factor

KW - Certolizumab pegol

KW - Crohn disease

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=84905723625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905723625&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2014.05.008

DO - 10.1016/j.gtc.2014.05.008

M3 - Article

C2 - 25110253

AN - SCOPUS:84905723625

VL - 43

SP - 457

EP - 478

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 3

ER -